Ulcerative colitis future or investigational therapies
|
Ulcerative colitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ulcerative colitis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Ulcerative colitis future or investigational therapies |
|
FDA on Ulcerative colitis future or investigational therapies |
|
CDC on Ulcerative colitis future or investigational therapies |
|
Ulcerative colitis future or investigational therapies in the news |
|
Blogs on Ulcerative colitis future or investigational therapies |
|
Risk calculators and risk factors for Ulcerative colitis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
Ongoing research
Recent evidence from the ACT-1 trial suggests that infliximab may have a greater role in inducing and maintaining disease remission.
An increased amount of colonic sulfate-reducing bacteria has been observed in some patients with ulcerative colitis, resulting in higher concentrations of the toxic gas hydrogen sulfide. The role of hydrogen sulfide in pathogenesis is unclear. It has been suggested that the protective benefit of smoking that some patients report is due to hydrogen cyanide from cigarette smoke reacting with hydrogen sulfide to produce the nontoxic isothiocyanate. Another unrelated study suggested sulfur contained in red meats and alcohol may lead to an increased risk of relapse for patients in remission.[1]
There is much research currently being done to elucidate further genetic markers in ulcerative colitis. Linkage with Human Leukocyte Antigen B-27, associated with other autoimmune diseases, has been proposed.
Low dose naltrexone is under study for treatment of Crohn's disease and ulcerative colitis.
References
- ↑ Roediger WE, Moore J, Babidge W. Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Dig Dis Sci 1997;42:1571-9. PMID 9286219.